News | December 26, 2023
BioVaxys executes LoI for major Immunotherapeutics technology acquisition
BioVaxys has been granted exclusivity while the parties work in good faith on the drafting of a definitive agreement
BioVaxys has been granted exclusivity while the parties work in good faith on the drafting of a definitive agreement
Transaction delivers KarXT, a first-in-class M1/ M4 muscarinic receptor agonist with differentiated efficacy and safety
The agreement grants Brinter the distribution rights of GrowInk bioinks in many countries
KBR will provide outreach, education and data analytics to support critical neuroscience research for the prevention and treatment of military members with CTE
10+ emerging markets, Japan & ANZ transition in final phase
Expands patient reach to remotest towns by furthering investment in GoApptiv
The company makes its maiden entry into Azerbaijan’s pharmaceutical market
Leading USA based genetic testing brand officially enters the Indian market
Dr. Reddy's Laboratories has been issued a Form 483 with three observations
his marks the 12th formulation facility under Akums, and the second in Baddi, a strategic move with an aim to enhance Akums’ manufacturing capabilities.
Subscribe To Our Newsletter & Stay Updated
